Health Care Knowledge

  Ibrutinib comes under the brand name Imbruvica. It is an anticancer medicine that belongs to a class of drugs called protein kinase inhibitors. The ibrutinib medication is available as immediate-release oral capsules and immediate-release oral tablets. Ibrutinib capsules for oral administration are available in the following dosage strengths: 70 mg and 140 mg. Although, ibrutinib tablets for oral administration are available in the following dosage strengths: 140 mg, 280 mg, 420 mg, and 560 mg.   Ibrutinib is used for the treatment of the following blood cancers in adults: Mantle Cell Lymphoma: Ibrutinib is prescribed for the treatment of adult patients with MCL (mantle cell lymphoma) who have received at least 1-prior therapy.   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Ibrutinib is prescribed for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).   Chronic Lymphocytic Leukemia/Small Lymphocytic Lym

  Gemcitabine is specifically a nucleoside analog and a chemotherapeutic agent. This agent was originally developed for its antiviral effects, but it is now recommended as an anticancer therapy to treat various cancers. The study of gemcitabine injection suggests that it is a cytidine analog with a couple of fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, this drug is transformed into its active metabolites that act by replacing the building blocks of nucleic acids during DNA elongation, arresting tumor growth, and promoting apoptosis of malignant cells. The structure, metabolism, and working of gemcitabine are identical to cytarabine, but gemcitabine has a wider spectrum of antitumor activity.   Gemcitabine is available as the strength of 200 mg for intravenous administration. This drug is marketed as Gemzar. Gemcitabine is approved by the FDA for the treatment of certain cancers which are listed below. It is also being investigated in other cancer and tumor ty